Telbivudine Treatment during Late Pregnancy Prevents Mother-to-Child Transmission of Hepatitis B Virus: A Retrospective Study
Table 3
ALT levels of the pregnant women during pregnancy and postpartum.
Group A (n=264)
Group B (n=136)
Group C (n=251)
P Group B vs. C
Baseline (U/L)
33.13±9.95
127.49±68.23
120.63±67.07
0.340
0-40
218 (82.6%)
0
0
0.369
41-80
46 (17.4%)
42 (30.9%)
90 (35.9%)
81-200
0
73 (53.68%)
134 (53.39%)
201-400
0
21 (15.44%)
26 (10.36%)
401-
0
0
1 (0.40%)
Before delivery (U/L)
32.89±9.25
53.13±14.88
42.00±12.01
<0.001
0-40
219 (83.0%)
31 (22.8%)
134 (53.4%)
<0.001
41-80
45 (17.0%)
97 (71.3%)
114 (45.4%)
81-200
0
8 (5.9%)
3 (1.2%)
201-400
0
0
0
401-
0
0
0
7 months postpartum (U/L)
27.24±8.21
60.18±14.12
31.06±1.66
<0.001
0-40
241 (91.3%)
3 (2.2%)
210 (83.7%)
<0.001
41-80
23 (8.7%)
116 (85.3%)
41 (16.3%)
81-200
0
17(12.5%)
0
201-400
0
0
0
401-
0
0
0
1 year postpartum (U/L)
26.54±7.85
58.83±1.16
29.01±8.66
<0.001
0-40
243 (92.0%)
4 (2.9%)
219 (87.3%)
<0.001
41-80
21 (8.0%)
119 (87.5%)
32 (12.7%)
81-200
0
13(9.6%)
0
201-400
0
0
0
401-
0
0
0
Values are reported as mean ± standard deviation, compared with t test; or number (percentage), compared with chi-square test or fisher's test, unless otherwise indicated. n, number of patients; ALT, alanine aminotransferase.
